Skip to main content

Clinical Trials Using Ibrutinib

Review the clinical trials studying ibrutinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients with Relapsed and/or Refractory Aggressive B-cell Lymphoma
Status: Active
Location: 59 locations
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Active
Location: 19 locations
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Status: Active
Location: 18 locations
Pembrolizumab, Ibrutinib, and Rituximab for the Treatment of Relapse or Refractory Primary Central Nervous System Lymphoma
Status: Active
Location: 10 locations
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Status: Active
Location: 8 locations
Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 8 locations
Ibrutinib with or without Methotrexate, Rituximab, Vincristine, and Procarbazine in Treating Patients with Newly Diagnosed or Refractory/Recurrent Primary or Secondary Central Nervous System Lymphoma
Status: Active
Location: 7 locations
A Study of Epcoritamab and Ibrutinib in People With Relapsed or Refractory Central Nervous System Lymphoma (CNSL)
Status: Active
Location: 7 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 3 locations
Ibrutinib, Temozolomide, Etoposide, Pegylated Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Rituximab in Treating Patients with Primary Central Nervous System Lymphoma
Status: Active
Location: 3 locations
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period.
Status: Active
Location: 3 locations
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
Status: Active
Location: 2 locations
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
Status: Active
Location: 2 locations
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Venetoclax and Ibrutinib or Acalabrutinib in Treating Patients with High-Risk Chronic Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Glofitamab Plus Ibrutinib with Obinutuzumab for the Treatment of Patients with Mantle Cell Lymphoma
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Epcoritamab plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Status: Active
Location: See ClinicalTrials.gov
Venetoclax and Ibrutinib in Treating Patients with Chronic or Small Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Status: Temporarily Closed to Accrual
Location: 101 locations
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida